Researchers at the University of California San Diego School of Medicine have found that individuals with depression who use psilocybin seek mental health care at rates similar to those who do not use the substance. Despite this, psilocybin users report a higher incidence of unmet mental health care needs, indicating they are not entirely replacing conventional therapy with psilocybin use. The findings are detailed in the journal Psychological Medicine.
Read More
Avery Eun, the study's first author and a second-year medical student, stated that these results are reassuring, showing that psilocybin users are not abandoning traditional mental health care. However, the higher perceived unmet needs among these users highlight an opportunity to better address the challenges they face in accessing adequate mental health services.
As psilocybin decriminalization progresses in the U.S., some professionals have expressed concern that people might opt for self-medication instead of seeking supervised care. This study, drawing on data from the 2024 National Survey on Drug Use and Health (NSDUH), is the first nationally representative analysis to assess the frequency of recent psilocybin use among people with depression.
The researchers analyzed data from 6,793 individuals aged 12 and older who experienced a major depressive episode within the past year. Key findings include:
- Approximately 7.3% of those who experienced a major depressive episode reported using psilocybin during the same period.
- There was no correlation between psilocybin use and lower utilization of various mental health treatments, including outpatient, inpatient, or telehealth services, nor was it associated with a decrease in prescribed depression medications.
- Psilocybin users reported a significantly higher perceived unmet need for mental health treatment (52.0%) compared to nonusers (33.9%).
- Users were typically younger, male, single, and employed full-time.
While clinical trials have shown psilocybin-assisted therapy to be effective in controlled settings, the researchers cautioned that naturalistic use occurs without those safeguards. Consequently, users might obtain psilocybin from inconsistent sources, impacting the safety and efficacy of their experiences.
The gap between perceived need and actual care may lead individuals to self-manage symptoms with psychedelics, a hypothesis that requires further investigation. The study also suggested that policy changes, such as the decriminalization of psilocybin, could enhance patient safety by reducing stigma and fostering open dialogue about treatment options.
Eun emphasized the importance of providers reassessing how they view psilocybin use among patients, viewing it as a potential entry point for discussions about therapeutic motivations and the adequacy of conventional care.